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ABSTRACT
Objective We examined temporal heart failure (HF) 
prescription patterns in a large representative sample 
of real- world patients in the UK, using electronic health 
records (EHR).
Methods From primary and secondary care EHR, we 
identified 85 732 patients with a HF diagnosis between 
2002 and 2015. Almost 50% of patients with HF were 
women and the median age was 79.1 (IQR 70.2–85.7) 
years, with age at diagnosis increasing over time.
Results We found several trends in pharmacological 
HF management, including increased beta blocker 
prescriptions over time (29% in 2002–2005 and 54% in 
2013–2015), which was not observed for mineralocorticoid 
receptor- antagonists (MR- antagonists) (18% in 2002–
2005 and 18% in 2013–2015); higher prescription rates 
of loop diuretics in women and elderly patients together 
with lower prescription rates of angiotensin- converting 
enzyme inhibitors and/or angiotensin II receptor blockers, 
beta blockers or MR- antagonists in these patients; little 
change in medication prescription rates occurred after 6 
months of HF diagnosis and, finally, patients hospitalised 
for HF who had no recorded follow- up in primary care 
had considerably lower prescription rates compared 
with patients with a HF diagnosis in primary care with or 
without HF hospitalisation.
Conclusion In the general population, the use of MR- 
antagonists for HF remained low and did not change 
throughout 13 years of follow- up. For most patients, few 
changes were seen in pharmacological management of HF 
in the 6 months following diagnosis.
INTRODUCTION
Heart failure (HF) is a common public health 
burden, with the prevalence of HF estimated 
at approximately 500 000 patients in the 
UK.1 2 Once diagnosed, initiation and up titra-
tion of guideline recommended therapies 
can reduce morbidity and mortality, although 
5- year survival still remains 20%–50%.3 4
Several observational studies have 
assessed treatment uptake in patients with 
HF following their diagnosis. These studies 
suggest that many patients did not receive 
guideline- recommended therapies or at low 
doses with sparse attempts for up titration.5–8 
Optimal treatment for effective disease 
management seems to be particularly chal-
lenging in elderly patients, women or patients 
with multiple comorbidities and contrain-
dications for treatments.7 8 At present, few 
data are available for prescription trends in 
patients with HF in the general population 
and even fewer data are available that shed 
light on medication use in patients with HF in 
the years prior to their HF diagnosis.
The CALIBER (CArdiovascular disease 
research using LInked Bespoke studies and 
Electronic health Records) resource curates 
primary and secondary care electronic health 
records (EHR) of 5 million individuals in the 
UK, including HF diagnosis and medication 
prescriptions.9 Given the amount of informa-
tion available, medication use of all patients 
with HF in the community may be investi-
gated—including those which are underrep-
resented in randomised clinical trials.
Therefore, we sought to examine HF treat-
ment prescription patterns following a HF 
diagnosis for the overall population as well 
as specific subgroups based on gender (eg, 
women), age (eg, elderly), social economic 
status and healthcare setting (eg, primary 
care or secondary care), in a large represen-
tative sample of real- world patients in the UK, 
using EHR.10
Strengths and limitations of this study
 ► Large cohort of patients with heart failure (HF) from 
primary and secondary care.
 ► Long follow- up period of almost 15 years.
 ► Unable to differentiate between HF subphenotypes 
such as HF with reduced, mid- range or preserved 
ejection fraction.
 ► Unknown treatment eligibility, contraindications or 
intolerances may affect the choice of treatment.
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Patients were selected from linked EHR in the UK, which 
consist of three linked databases: The Clinical Prac-
tice Research Datalink (CPRD) with primary care EHR, 
Hospital Episodes Statistics (HES) containing coded diag-
noses and surgical procedures from inpatient hospital 
admissions and the Office for National Statistics registry 
containing cause- specific mortality data.10 Previous work 
has shown that these patients are representative of the 
general population in the UK.11 12
Study population
Patients were included at their first record of HF from 
CPRD or HES between 1 January 2002 and 31 December 
2015. In CPRD, events were defined by a diagnosis of 
HF based on Read (V.2) controlled clinical terminology 
codes (National Health Service- coded clinical terms) and 
in HES by a diagnosis of HF based on International Clas-
sification of Diseases 10th revision (ICD-10) codes. The 
same HF diagnosis codes were used as in previous papers, 
with in addition several newer Read codes listed in online 
supplemental table 1.4 13 All patients were eligible for 
inclusion if they were aged 18 years or older and were 
registered with a GP for at least 1 year prior to diagnosis of 
HF, in a practice that had at least 1 year of up- to- standard 
data recording in CPRD (data quality check). The first 
record of HF from CPRD or HES was considered the 
index date. Individuals were censored at the earliest date 
from the date of deregistration in CPRD, the last data 
collection date of a practice in CPRD, the date of death or 
at the study end date (31 December 2015). Data on EHR 
phenotyping variables from patients with HF up to 3 years 
prior to index date were included in this study.
Patient and public involvement
There was no patient or public involvement in this 
research.
EHR phenotyping variables
Baseline patient characteristics were based on records 
from CPRD and/or HES prior to index date, including 
demographics (age, sex, ethnicity, social deprivation), 
cardiovascular risk factors (smoking, body mass index, 
diastolic blood pressure and systolic blood pressure and 
estimated glomerular filtration rate), comorbidities (a 
medical history of atrial fibrillation, chronic obstructive 
pulmonary disease, diabetes, hypertension, ischaemic 
heart disease, valvular disease and history of cancer) and 
medication prescription.
CPRD includes all prescriptions from the general prac-
tice. Prescriptions in CPRD were classified as RAS inhib-
itors (angiotensin- converting enzyme inhibitors and/or 
angiotensin II receptor blockers), beta blockers, miner-
alocorticoid receptor- antagonists (MR- antagonists) and 
loop diuretics. Definitions of these variables could be 
found online at http://www. caliberresearch. org/ portal/.
Medication prescription for RAS inhibitors, beta 
blockers, MR- antagonists and loop diuretics was identified 
between 3 years prior to HF diagnosis up to 3 years after 
HF diagnosis per the following increments: −36 months 
to −24 months, −24 months to −18 months, −18 months 
to −12 months, −12 months to −6 months, −6 months to 
−3 months, −3 months to HF diagnosis, HF diagnosis to 
+3 months, +3 months to +6 months, +6 months to +12 
months, +12 months to +18 months, +18 months to +24 
months and +24 to +36 months.
Healthcare setting was characterised as primary care 
only (no HF hospitalisation), secondary care only (no 
Read HF diagnosis recorded in primary care) or HF 
diagnosis in both primary and secondary care. Ethnicity 
records from CPRD and HES were combined and cate-
gorised as Caucasian, Asian, Black or Other. Social depri-
vation was measured as quintiles of the index of multiple 
deprivation of the geographical area of the primary care 
practice, a score was calculated based on seven indices of 
deprivation: income, employment, health and disability, 
education, barrier to housing and services, crime and 
living environment.14 Smoking status in CPRD was classi-
fied as never, ex- smokers or current smokers.
Statistical analysis
Patient characteristics were summarised as mean (SD) or 
median (IQR) for continuous variables and percentages 
for categorical variables. The percentage of patients with 
HF prescribed pharmacological treatments was calcu-
lated per increment and per time period as defined by 
publication year of previous European Society of Cardi-
ology (ESC) guidelines (2001, 2005, 2008 and 2012)1 15–18: 
2002–2005, 2006–2008, 2009–2012 and 2013–2015. In 
addition to the overall cohort, we investigated several 
subgroups: age (<vs≥ 75 years old), sex (men vs women), 
social economic status (lowest quintile of social depriva-
tion vs the rest) and setting (only follow- up in primary 
care vs only in secondary care vs follow- up in primary care 




We identified 85 732 patients with a HF diagnosis. The 
study flow diagram is found in online supplemental figure 
1. Median follow- up after HF diagnosis (index date) was 
2.1 years (0.6–4.5 years). Table 1 shows the overall base-
line patient characteristics and per time period 2002–
2005, 2006–2008, 2009–2012 and 2013–2015. Almost 
50% of patients were women and the median age was 79.1 
(70.2–85.7) years, with age at HF diagnosis increasing 
over time. Overall, many patients with HF had comorbid-
ities, most common were hypertension (61%), ischaemic 
heart disease (44%) and atrial fibrillation (37%), with 
increasing numbers of patients with comorbidities over 
time. Approximately 40% (n=34 489) of patients were 
followed- up in primary care after a HF hospitalisation, 
 on M












pen: first published as 10.1136/bm



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































pen: first published as 10.1136/bm





4 Uijl A, et al. BMJ Open 2021;11:e043290. doi:10.1136/bmjopen-2020-043290
Open access 
20% (n=15 330) of patients were only known in primary 
care and never hospitalised for HF and the remaining 
40% (n=35 913) of patients had no follow- up in primary 
care after HF hospitalisation.
Overall prescription patterns
Overall prescription patterns are shown in figure 1. Many 
patients were prescribed medication before HF diagnosis, 
especially RAS inhibitors (20% in 2002–2005 to 46% in 
2013–2015). Over time, beta blocker prescription after 
HF diagnosis increased from 30% in 2002–2005 to 55% 
in 2013–2015. Throughout the follow- up of 13 years, 
there were little observed changes for MR- antagonist 
uptake, this remained at 20% throughout time after HF 
diagnosis. The largest observed changes in prescription 
patterns occurred between 6 months before and after HF 
diagnosis (figure 1). Approximately 20% of patients with 
HF were prescribed a loop diuretic up to 3 years prior to 
HF diagnosis.
Setting-specific prescription patterns
Setting- specific prescription patterns are shown in 
figure 2. Patients followed- up in primary care after HF 
hospitalisation had the highest prescription rates for all 
types of medication. Over time, the prescription for loop 
diuretics, RAS inhibitors and beta blockers converged 
Figure 1 The percentage of patients with HF receiving prescriptions of RAS inhibitors, beta blockers, MR- antagonists, loop 
diuretics per months since HF diagnosis. HF, heart failure; MR- antagonists, mineralocorticoid receptor antagonists; RAS 
inhibitors, angiotensin- converting enzyme inhibitors and/or angiotensin II receptor blockers.
Figure 2 The percentage of patients with HF receiving prescriptions of RAS inhibitors, beta blockers and MR- antagonists per 
months since HF diagnosis, stratified by setting (primary care only, secondary care only, both primary and secondary care). HF, 
heart failure; MR- antagonists, mineralocorticoid receptor antagonists; RAS inhibitors, angiotensin- converting enzyme inhibitors 
and/or angiotensin II receptor blockers.
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together. In these patients, the prescription for MR- antag-
onists increased over time after HF diagnosis from 20% in 
2002–2005 to 30% in 2013–2015.
Patients known in primary care but never hospitalised 
for HF had lower prescription rates for all types of treat-
ment compared with patients with primary care follow- up 
and at least one HF hospitalisation. Mainly loop diuretics 
were less prescribed in these patients and the prescrip-
tion of loop diuretics decreased over time with 65% of 
patients receiving loop diuretics after HF diagnosis in 
2002–2005 compared with just over 40% in 2013–2015.
Patients hospitalised for HF but without a HF diagnosis 
in primary care had the lowest prescriptions rates for 
loop diuretics, RAS inhibitors and beta blockers, which 
remained stable over time (50%, 45% and 45% in 2013–
2015, respectively). MR- antagonists were only prescribed 
in 13% of patients after HF diagnosis, this was similar for 
each time period.
Age-specific prescription patterns
Differences in prescription according to age catego-
ries are shown in figure 3. The observed increase in 
prescriptions for RAS inhibitors, beta blockers and 
MR- antagonists between 6 months before HF diagnosis 
and 6 months after HF diagnosis was less pronounced in 
elderly patients. The average increase in elderly patients 
was 12%, 7%, 8% for RAS inhibitors, beta blockers and 
MR- antagonists, respectively, while younger patients had 
an average increase of 23%, 19% and 13% for RAS inhib-
itors, beta blockers and MR- antagonists, respectively. On 
the other hand, a higher proportion of elderly patients 
was treated with loop diuretics compared with younger 
patients, both before and after HF diagnosis (45% before 
and 63% after HF diagnosis in elderly compared with 27% 
before and 47% after HF diagnosis for younger patients 
in 2013–2015). After HF diagnosis, a higher percentage 
of younger patients was prescribed with RAS inhibitors 
and beta blockers compared with older patients.
Sex-specific prescription patterns
Differences in prescription between men and women 
are shown in figure 4. Loop diuretics were prescribed 
in a higher proportion of women compared with men, 
this difference was already present prior to HF diagnosis 
Figure 3 The percentage of patients with HF receiving prescriptions of RAS inhibitors, beta blockers and MR- antagonists per 
months since HF diagnosis, stratified by age. HF, heart failure; MR- antagonists, mineralocorticoid receptor antagonists; RAS 
inhibitors, angiotensin- converting enzyme inhibitors and/or angiotensin II receptor blockers.
Figure 4 The percentage of patients with HF receiving prescriptions of RAS inhibitors, beta blockers and MR- antagonists per 
months since HF diagnosis, stratified by sex. HF, heart failure; MR- antagonists, mineralocorticoid receptor antagonists; RAS 
inhibitors, angiotensin- converting enzyme inhibitors and/or angiotensin II receptor blockers.
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where 6 months before diagnosis, 30% of women and 
20% of men were prescribed a loop diuretic. After HF 
diagnosis, the most prescribed medication for women 
was a loop diuretic, while a higher proportion of men was 
prescribed a RAS inhibitor. Men were also more often 
prescribed RAS inhibitors, beta blockers and MR- antago-
nists after HF diagnosis compared with women.
Social economic status-specific prescription patterns
Social economic status- specific prescription patterns are 
shown in figure 5. We did not observe any discernible 
differences between patients in low versus high social 
economic areas (highest quintile of social economic 
deprivation).
DISCUSSION
In this large- scale study of 85 732 patients with HF, we 
investigated treatment prescription patterns in a repre-
sentative sample of real- world patients with HF in the UK 
between 2002 and 2015. We found three important trends 
in pharmacological HF management: (a) increased use 
of beta blockers, whereas there was no increased uptake 
of MR- antagonists over 13 years follow- up, (b) prescrip-
tion rates remained almost unchanged after the first 6 
months following a HF diagnosis and, finally, (c) higher 
rates of loop diuretics in women and elderly patients 
together with lower prescription rates for RAS inhibitors, 
beta blockers or MR- antagonists.
Temporal trends in HF medication
Even though prescription rates increased over time from 
2002 to 2015, overall prescription rates remained low. 
This is in line with previously published studies.5–8 19 Low 
prescription rates could be attributed to the mixed HF 
cases found in EHR. We were unable to distinguish HF 
with reduced ejection fraction (HFrEF), HF with mid- 
range ejection fraction and HF with preserved ejection 
fraction (HFpEF) based on medical records, thereby 
including known differences in treatment recommenda-
tions for these HF phenotypes.1
We found no major differences in prescription behaviour 
after the publication of ESC guidelines; however, we did 
observe the gradual increase of beta blockers as one of 
the cornerstones of HF treatment. RAS inhibitors were 
prescribed in a high proportion of patients throughout 
the years of the study, presumably because the first clin-
ical trials in HFrEF showing a beneficial effect were from 
the late 1980s and early 1990s.20 Surprisingly, we found 
lower than expected prescription rates for MR- antag-
onists, which persisted over the years included in this 
study. This is in spite of multiple clinical trials which have 
shown benefit in patients with HFrEF.21 Besides HFrEF 
trials, a post hoc analysis of the Treatment of Preserved 
Cardiac Function Heart Failure With an Aldosterone 
Antagonist (TOPCAT) trial in 2015 (Spironolactone, 
an MR- antagonist, for HFpEF) reported regional differ-
ences between Americas and Russia/Georgia, where the 
American patients showed clinical benefits.22 The Amer-
ican College of Cardiology/American Heart Association 
focused update on HF management in 2017 gave spirono-
lactone a grade IIb recommendation, thereby stimulating 
that selected patients with HFpEF could be treated with 
spironolactone to decrease rehospitalisations.23
HF medication initiation following diagnosis
Most activity in treatment prescription behaviour was 
observed between 6 months before and 6 months after 
HF diagnosis. After the 6 month mark, we did not observe 
many patients starting any of the medication investigated. 
This is in line with previous studies showing that there 
are few changes in medication use and little up titration 
of medication after treatment initiation.5 24 This leaves 
room for improvement in starting treatment at any time 
point following a HF diagnosis, for example, if patients 
hospitalised with acute HF do not immediately tolerate 
negative inotropic medication such as beta blockers.
Figure 5 The percentage of patients with HF receiving prescriptions of RAS inhibitors, beta blockers and MR- antagonists 
per months since HF diagnosis, stratified by social status (highest quintile of social deprivation vs the rest). HF, heart failure; 
MR- antagonists, mineralocorticoid receptor antagonists; RAS inhibitors, angiotensin- converting enzyme inhibitors and/or 
angiotensin II receptor blockers.
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Impact of HF hospitalisation on medication prescription
We found differences in prescription patterns between 
patients with a HF diagnosis recorded in different settings. 
Patients with a primary care HF diagnosis without HF 
hospitalisation had much lower prescription rates of loop 
diuretics compared with patients with a HF diagnosis 
recorded in both primary and secondary care. It could 
be that these patients have less severe fluid overload or 
symptoms that require alleviation by loop diuretics, and 
thus less severe HF.
Previously it was shown that there are differences 
in overall 5- year survival of patients with HF diagnosis 
recorded in primary care only, secondary care only and 
in both, with the worst survival seen in patients with HF 
identified only in secondary care and the best survival 
for patients with HF identified in primary care with or 
without hospitalisation for HF.4 Here, we advance current 
knowledge by showing that there are longitudinal differ-
ences in HF care of patients with diagnosis recorded in 
different settings.
In this study, almost 40% of patients did not have a GP 
record of a HF diagnosis after a HF hospitalisation. One 
reason could be that GPs do not formally register HF with 
a Read diagnosis code, but rather in free- text descriptions. 
However, there could also be a potential quality of care 
gap or failure of communication between secondary and 
primary care, where patients are not treated optimally. 
Primary care is the basis of many healthcare systems, 
including the UK. If there is no HF diagnosis recorded 
in primary care after HF hospitalisation, which is shown 
to be indicative for worse survival, rehospitalisation and 
severity of disease, this could be detrimental for patients.
HF treatment in women and elderly
Over time, we observed that HF was diagnosed at a later 
age, with the median almost 80 years old between 2013 
and 2015. This is also seen in many other developed 
countries where the mean age of HF diagnosis is over 70 
years old.25 26
We observed lower prescription rates in elderly patients 
compared with younger patients for RAS inhibitors, beta 
blockers and MR- antagonists, although the difference 
in MR- antagonists was less pronounced. Many elderly 
patients were already using RAS inhibitors prior to HF 
diagnosis, therefore, the increase in prescription rate is 
not as steep as compared with younger patients with HF 
who are prescribed less medication prior to HF diagnosis. 
This could be explained by the presence of comorbidities, 
such as atrial fibrillation or hypertension, which are much 
more prevalent among elderly compared with younger 
patients, and for which these elderly patients could be 
prescribed RAS inhibitors.
Remarkably, the difference between prescription of 
RAS inhibitors and beta blockers prior to HF diagnosis 
was less than 5% for men and women, and only after 
the diagnosis of HF was a higher proportion of men 
prescribed a RAS inhibitor or beta blocker. This could 
potentially be related to the fact that elderly women are 
more likely to develop HFpEF and, therefore, tend to be 
treated symptomatically with loop diuretics, rather than 
with RAS inhibitors and beta blockers. However, litera-
ture also shows that there are differences in treatment 
prescription in men and women with HFrEF, for which 
there is no obvious explanation.27
Both elderly patients and women received more loop 
diuretics. However, this could potentially be harmful, 
especially for elderly, since loop diuretics could lead to 
electrolyte disturbances and acute kidney injury.28 Elderly 
patients are often excluded or underrepresented in 
clinical trials, therefore, current recommendations lack 
convincing evidence in the elderly population. However, 
recently a large meta- analysis reported a significant effect 
of beta blockers on overall mortality regardless of age.29 
These studies indicate that elderly patients also benefit 
from HF- specific medication and should be a choice of 
treatment for these patients, besides loop diuretics for 
symptom alleviation. However, elderly patients might 
have more contraindications or intolerances to RAS 
inhibitors, beta blockers and MR- antagonists and might, 
therefore, be more often treated with loop diuretics for 
symptom control.
Strengths and limitations
Strengths of this study are the large cohort of patients with 
HF and a long follow- up period. Patient records available 
are representative of the general UK population, which 
provides evidence for the validity of using these EHR for 
research.11 12 However, we were limited by the inability to 
differentiate between HF phenotypes based on medical 
records, since there was no access to detailed echocardi-
ography estimates to assess systolic function. Nor did we 
have information on New York Heart Association class 
or N- terminal pro–B- type natriuretic peptide biomarker 
levels. Furthermore, treatments administered during a 
hospital admission or discharge were not reported, such 
as intravenous inotropic agents. However, CPRD includes 
all prescriptions from general practice to non- hospitalised 
patients. We were also unable to assess patients’ symptom 
class (which would affect their eligibility for treatments 
such as MR- antagonists) and contraindications or intoler-
ances that may affect the choice of medication.
CONCLUSION
The results of this population- based study of over 80 000 
patients with HF in England show variable increases in 
uptake of evidence- based treatments, with no change 
in prescription of MR- antagonists over 13 years but an 
increase in beta blocker use. Large differences were 
observed between HF patient groups, with lowest prescrip-
tion rates of RAS inhibitors, beta blockers and MR- antag-
onists in women, elderly patients and those without a HF 
diagnosis in primary care. Most changes in prescriptions 
occurred within 6 months prior to or 6 months following 
a diagnosis of HF, with little change, thereafter suggesting 
further opportunities to improve HF management.
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